About KEYTRUDA in metastatic colorectal cancer (CRC)

KEYTRUDA® (pembrolizumab) in metastatic colorectal cancer (CRC)

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

KEYTRUDA as monotherapy is indicated for:

	Metastatic colorectal cancer
For use in	The first-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults1
Dosing schedule	The recommended dose is either 200 mg every 3 weeks or 400 mg every 6 weeks, administered as an intravenous infusion over 30 minutes1
Duration of treatment	Treat until disease progression or unacceptable toxicity1
Clinical trial	KEYNOTE-177 was a Phase 3, multicentre, open-label, active-controlled study of adult patients with metastatic MSI-H/dMMR colorectal cancer, randomised 1:1 to receive pembrolizumab or investigator’s choice of chemotherapy regimens2 Click here to download the KEYNOTE-177 clinical data presentation Download

References

1. KEYTRUDA Summary of Product Characteristics.
2. André T, Shiu K-K, Kim TW, et al. N Engl J Med. 2020;383:2207-2218.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website